BR112013000341A2 - estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr) - Google Patents
estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr)Info
- Publication number
- BR112013000341A2 BR112013000341A2 BR112013000341A BR112013000341A BR112013000341A2 BR 112013000341 A2 BR112013000341 A2 BR 112013000341A2 BR 112013000341 A BR112013000341 A BR 112013000341A BR 112013000341 A BR112013000341 A BR 112013000341A BR 112013000341 A2 BR112013000341 A2 BR 112013000341A2
- Authority
- BR
- Brazil
- Prior art keywords
- kdr
- vegfr
- binding
- factor
- recombinant antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2010/053109 WO2012004631A2 (en) | 2010-07-07 | 2010-07-07 | Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013000341A2 true BR112013000341A2 (pt) | 2017-09-26 |
Family
ID=45441588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013000341A BR112013000341A2 (pt) | 2010-07-07 | 2010-07-07 | estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr) |
Country Status (7)
Country | Link |
---|---|
US (1) | US9193792B2 (pt) |
EP (1) | EP2591002A2 (pt) |
JP (1) | JP2013540420A (pt) |
KR (1) | KR102007045B1 (pt) |
CN (1) | CN103119063B8 (pt) |
BR (1) | BR112013000341A2 (pt) |
WO (1) | WO2012004631A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2729303A1 (en) * | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
EP2903645A2 (en) * | 2012-10-05 | 2015-08-12 | Kadmon Corporation, LLC | Treatment of ocular disorders |
CN105007939B (zh) * | 2012-10-05 | 2018-10-19 | 卡德门企业有限公司 | 人抗vegfr-2/kdr抗体 |
CN105330739B (zh) * | 2014-08-12 | 2020-12-25 | 中美华世通生物医药科技(武汉)有限公司 | 与人血管内皮生长因子特异性结合的抗体或其抗原结合片段及其用途 |
WO2016057726A2 (en) | 2014-10-07 | 2016-04-14 | Kadmon Corporation, Llc | Human anti-vegfr-2/kdr antibodies |
CN105628910A (zh) * | 2014-11-07 | 2016-06-01 | 上海中信国健药业股份有限公司 | 一种针对vegf靶向治疗药物的生物学活性检测方法 |
EP3307772B1 (en) * | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
EP3436480A4 (en) | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION |
CA3026236C (en) | 2016-06-03 | 2021-01-26 | Samsung Life Public Welfare Foundation | Method for screening antibody using patient-derived tumor spheroids |
CN106892980B (zh) * | 2017-01-25 | 2020-08-04 | 长春金赛药业有限责任公司 | 抗vegfr2单克隆抗体及其应用 |
CN113330112A (zh) * | 2018-12-21 | 2021-08-31 | 得克萨斯大学体系董事会 | 磷酸化的dicer抗体及其使用方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
IL144578A0 (en) * | 1999-01-29 | 2002-05-23 | Imclone Systems Inc | Antibodies specific to kdr and uses thereof |
US20020064528A1 (en) * | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
AU2985800A (en) * | 1999-02-09 | 2000-08-29 | Arch Development Corporation | Genes encoding the 5h7 antibody and methods for conferring programmed cell deathproperties to cells |
US6342221B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody conjugate compositions for selectively inhibiting VEGF |
US7414111B2 (en) * | 2001-09-19 | 2008-08-19 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
WO2009066655A1 (ja) * | 2007-11-19 | 2009-05-28 | Kagoshima University | アポトーシス誘導能を有するヒト抗体 |
CN101245106B (zh) * | 2007-12-04 | 2011-07-20 | 澳赛尔斯生物技术(上海)有限公司 | 抗vegf受体单克隆抗体及其制备方法和应用 |
EP2350660B1 (en) * | 2008-10-24 | 2016-03-09 | FUJIFILM Corporation | Immobilization substrate and method for producing the same |
JP5835204B2 (ja) | 2012-12-20 | 2015-12-24 | 信越化学工業株式会社 | レジスト材料及びこれを用いたパターン形成方法 |
-
2010
- 2010-07-07 EP EP10854375.2A patent/EP2591002A2/en not_active Withdrawn
- 2010-07-07 JP JP2013517561A patent/JP2013540420A/ja active Pending
- 2010-07-07 CN CN201080069006.4A patent/CN103119063B8/zh active Active
- 2010-07-07 WO PCT/IB2010/053109 patent/WO2012004631A2/en active Application Filing
- 2010-07-07 BR BR112013000341A patent/BR112013000341A2/pt not_active Application Discontinuation
- 2010-07-07 US US13/808,295 patent/US9193792B2/en active Active
- 2010-07-07 KR KR1020137002847A patent/KR102007045B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2591002A2 (en) | 2013-05-15 |
WO2012004631A2 (en) | 2012-01-12 |
WO2012004631A3 (en) | 2012-07-19 |
CN103119063A (zh) | 2013-05-22 |
US9193792B2 (en) | 2015-11-24 |
US20140199301A1 (en) | 2014-07-17 |
CN103119063B8 (zh) | 2016-10-12 |
CN103119063B (zh) | 2016-06-29 |
JP2013540420A (ja) | 2013-11-07 |
KR102007045B1 (ko) | 2019-08-05 |
KR20130132739A (ko) | 2013-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013000341A2 (pt) | estruturas de anticorpos recombinantes ligando-se e bloqueando o crescimento da atividade vascular endotelial de fator 2 (vegfr-2/kdr) | |
UA110932C2 (uk) | Біспецифічне двовалентне антитіло анти-vegf/анти-ang-2 | |
LTPA2019011I1 (lt) | CGRP antikūnai | |
JP2011256183A5 (pt) | ||
BR112012021374A2 (pt) | " plataforma de pernas atirantadas " | |
BR112013023743A2 (pt) | anticorpo de fator de tecidos humanos e usos do mesmo | |
DK3050576T3 (da) | Pegylerede rekombinante forbindelser af humant væksthormon | |
EA201500132A1 (ru) | Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний | |
BR112014028413A2 (pt) | usos terapêuticos de proteínas do fator de crescimento de fibroblastos 21 . | |
BR112014004936A2 (pt) | polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo | |
BR112013024493A2 (pt) | cristais de anticorpo antiesclerostina e formulações dos mesmos | |
BR112013014235A2 (pt) | anticorpos anti-ccr4 e usos dos mesmos | |
BR112012030941A2 (pt) | proteína de fusão tendo atividade de fator vii | |
FI20105825A (fi) | Veriryhmästatuksen käyttö III | |
PL2601951T3 (pl) | Kompozycja farmaceutyczna do leczenia krwawienia spowodowanego przez zaburzenia krzepnięcia krwi i stosowanie tej kompozycji | |
DE102011001189A8 (de) | Mikroelektrode zur Zurückweisung von Bewegungsartefakten | |
FR2962650B1 (fr) | Composition d'immunoglobulines humaines concentrees | |
ZA201305031B (en) | Recombinant antibodies to the vascular endothelial growth factor (vegf) which are obtained by means of matagenesis of variable regions | |
PL2524693T3 (pl) | Farmaceutyk do zapobiegania lub leczenia chorób, którym towarzyszy angiogeneza tkanki oka i/lub zwiększona przepuszczalność naczyń krwionośnych oka | |
IT1400545B1 (it) | Procedimento per la preparazione di tessuto biologico per protesi biologiche. | |
FR2958159B1 (fr) | Compostion cosmetique ou pharmaceutique | |
DK3485883T3 (da) | Metoder til behandling af øjensygdomme forbundet med betændelse og vaskulær spredning | |
CY1121111T1 (el) | Συνθεσεις ανταγωνιστων toy vegf και χρησεις αυτων | |
BR112013014997A2 (pt) | interações fungicidas sinérgicas de 5-fluorcitosina e outros fungicidas | |
FI20106078A (fi) | Puukuitupitoisen jakeen käsittely |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |